Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
AffiliationUniv Arizona, Dept Med
niv Arizona, Banner Univ Med Ctr Tucson, Dept Hematol Oncol
MetadataShow full item record
PublisherHINDAWI PUBLISHING CORP
CitationRefractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review 2016, 2016:1 Case Reports in Oncological Medicine
RightsCopyright © 2016 Muhammad Husnain et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractPatients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the first-in-class human monoclonal antibody against CD38 cells which was studied in phase I/II trials for treatment of these patients with relapsed refractory multiple myeloma. It showed an overall response rate of 36% and a median overall survival (OS) of 17 months in these patients. We report a case of 40-year-old man with immunoglobulin D (IgD) multiple myeloma whose disease was refractory to at least 5 different chemotherapy regimens including proteasome inhibitors and immunomodulatory drugs. The clinical studies assessing daratumumab did not include any patients with IgD myeloma which is a rare form of multiple myeloma and to our knowledge is the first study reporting use of daratumumab in IgD myeloma.
NoteOpen Access Journal.
VersionFinal published version